(Q40892941)

24 September 2017

1 reference

title

Future directions in the development of new antitubercular drugs. Where do we go from here? (English)

1 reference

24 September 2017

Yew WW

1

1 reference

24 September 2017

Chau CH

series ordinal

2

1 reference

24 September 2017

publication date

1 June 1997

1 reference

24 September 2017

1 reference

24 September 2017

volume

10

1 reference

24 September 2017

issue

6

1 reference

24 September 2017

page(s)

405-410

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-199710060-00001

24 September 2017

exact match

0 references

cites work

In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis

1 reference

12 December 2020

Activity of aminosidine (paromomycin) for Mycobacterium tuberculosis and Mycobacterium avium

1 reference

12 December 2020

Genetic analysis of superoxide dismutase, the 23 kilodalton antigen of Mycobacterium tuberculosis

1 reference

12 December 2020

In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis

1 reference

12 December 2020

Global tuberculosis incidence and mortality during 1990-2000.

1 reference

12 December 2020

Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group

1 reference

12 December 2020

The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment

1 reference

12 December 2020

Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.

1 reference

12 December 2020

Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction

1 reference

12 December 2020

Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team

1 reference

12 December 2020

A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis

1 reference

12 December 2020

A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council

1 reference

12 December 2020

Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis

1 reference

12 December 2020

The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis

1 reference

12 December 2020

Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies

1 reference

12 December 2020

Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis

1 reference

12 December 2020

The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis

1 reference

12 December 2020

Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis

1 reference

12 December 2020

Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria

1 reference

12 December 2020

Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents?

1 reference

12 December 2020

Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects

1 reference

12 December 2020

Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice

1 reference

12 December 2020

Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin.

1 reference

12 December 2020

In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis

1 reference

12 December 2020

Why sequence the genome of Mycobacterium tuberculosis?

1 reference

12 December 2020

Molecular mechanisms of isoniazid: a drug at the front line of tuberculosis control

1 reference

12 December 2020

Activity of levofloxacin in a murine model of tuberculosis

1 reference

12 December 2020

Tuberculosis: a global overview of the situation today

1 reference

12 December 2020

Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. G.E.T.I.M. (Group for the Study and Treatment of Resistant Mycobacterial Infection)

1 reference

12 December 2020

inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis

1 reference

12 December 2020

In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin

1 reference

12 December 2020

In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria

1 reference

12 December 2020

In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355).

1 reference

12 December 2020

Anti-tuberculosis medication and the liver: dangers and recommendations in management

1 reference

12 December 2020

Monoclonal antibodies demonstrate that superoxide dismutase contributes to protection of Nocardia asteroides within the intact host

1 reference

12 December 2020

Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections.

1 reference

12 December 2020

Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis

1 reference

12 December 2020

Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages

1 reference

12 December 2020

Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice

1 reference

12 December 2020

Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells

1 reference

12 December 2020

The promise of immunotherapy for tuberculosis

1 reference

12 December 2020

Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa.

1 reference

12 December 2020

Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages

1 reference

12 December 2020

In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis

1 reference

12 December 2020

Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis.

1 reference

12 December 2020

Activation of macrophages to inhibit proliferation of Mycobacterium tuberculosis: comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages.

1 reference

12 December 2020

Do beta-lactam-beta-lactamase inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary tuberculosis?

1 reference

12 December 2020

Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis

1 reference

12 December 2020

Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals

1 reference

12 December 2020

In-vitro activity of quinolones and macrolides against mycobacteria.

1 reference

12 December 2020

Approaches to the development of new antituberculosis drugs

1 reference

12 December 2020

In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis

1 reference

12 December 2020

Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations

1 reference

12 December 2020

Sustained release of isoniazid in vivo from a single implant of a biodegradable polymer

1 reference

12 December 2020

Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis

1 reference

12 December 2020

Rifabutin (ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases

1 reference

12 December 2020

In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains

1 reference

12 December 2020

Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis

1 reference

12 December 2020

10.2165/00002512-199710060-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

24 September 2017

1014693073

0 references

1 reference